- Home
- RMTI vs MURA Comparison
RMTI vs MURA Comparison
Compare RMTI & MURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMTI
- MURA
- Stock Information
- Founded
- RMTI 1994
- MURA 2013
- Country
- RMTI United States
- MURA Ireland
- Employees
- RMTI N/A
- MURA N/A
- Industry
- RMTI Biotechnology: Pharmaceutical Preparations
- MURA
- Sector
- RMTI Health Care
- MURA
- Exchange
- RMTI Nasdaq
- MURA Nasdaq
- Market Cap
- RMTI 71.1M
- MURA 67.4M
- IPO Year
- RMTI 1998
- MURA N/A
- Fundamental
- Price
- RMTI $1.62
- MURA $3.70
- Analyst Decision
- RMTI Strong Buy
- MURA Strong Buy
- Analyst Count
- RMTI 2
- MURA 5
- Target Price
- RMTI $6.00
- MURA $16.00
- AVG Volume (30 Days)
- RMTI 201.6K
- MURA 88.4K
- Earning Date
- RMTI 03-20-2025
- MURA 03-11-2025
- Dividend Yield
- RMTI N/A
- MURA N/A
- EPS Growth
- RMTI N/A
- MURA N/A
- EPS
- RMTI N/A
- MURA N/A
- Revenue
- RMTI $98,917,000.00
- MURA N/A
- Revenue This Year
- RMTI $22.58
- MURA N/A
- Revenue Next Year
- RMTI N/A
- MURA N/A
- P/E Ratio
- RMTI N/A
- MURA N/A
- Revenue Growth
- RMTI 22.37
- MURA N/A
- 52 Week Low
- RMTI $1.35
- MURA $2.87
- 52 Week High
- RMTI $5.15
- MURA $5.38
- Technical
- Relative Strength Index (RSI)
- RMTI 41.26
- MURA 47.58
- Support Level
- RMTI $1.49
- MURA $3.22
- Resistance Level
- RMTI $1.74
- MURA $3.84
- Average True Range (ATR)
- RMTI 0.11
- MURA 0.21
- MACD
- RMTI 0.00
- MURA -0.00
- Stochastic Oscillator
- RMTI 44.12
- MURA 53.68
About RMTI Rockwell Medical Inc.
Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, and acid and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate among others.
About MURA Mural Oncology plc
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.